4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Impact · against what's priced in

FDMT is advancing its lead gene therapy, 4D-150, through Phase III trials for wet AMD and planning a trial expansion into diabetic macular edema (DME) later this year. These developments provide clear near-term clinical catalysts and potential for market expansion.

FDMT+0.40

No priced-in read yet